Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma

Head and Neck

Volumn 36, Issue 7, 2014, Pages 1039-1043

  Sandulache, Vlad C ^a   Hamblin, John S ^a   Skinner, Heath D ^b   Kubik, Mark W ^a   Myers, Jeffrey N ^b   Zevallos, Jose P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

diabetes mellitus; laryngeal cancer; metformin; radiation; survival

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG USE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LARYNGEAL SQUAMOUS CELL CARCINOMA; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REGIONAL METASTASIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; AGED; FOLLOW UP; LARYNX TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY;

AGED; CARCINOMA, SQUAMOUS CELL; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LARYNGEAL NEOPLASMS; METFORMIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84902550277     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23409     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Chen AY, Fedewa S, Zhu J,. Temporal trends in the treatment of early- and advanced-stage laryngeal cancer in the United States, 1985-2007. Arch Otolaryngol Head Neck Surg 2011; 137: 1017-1024.
3. Hoffman HT, Porter K, Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116 (9 Pt 2 Suppl 111): 1-13.
4. Gilbert J, Cmelak A, Shyr Y, et al. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer 2008; 113: 186-192.
5. Willey CD, Murphy BA, Netterville JL, et al. A phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. Int J Radiat Oncol Biol Phys 2007; 67: 1323-1331.
6. Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011; 81: 915-922.
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
8. Ujpál M, Barabás J, Kovalszky I, et al. A preliminary comparative study of the prognostic implications of type 2 diabetes mellitus for patients with primary gingival carcinoma treated with surgery and radiation therapy. J Oral Maxillofac Surg 2007; 65: 452-456.
9. Bosetti C, Rosato V, Polesel J, et al. Diabetes mellitus and cancer risk in a network of case-control studies. Nutr Cancer 2012; 64: 643-651.
10. Noto H, Goto A, Tsujimoto T, Noda M,. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012; 7: e33411.
11. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
12. Aljada A, Mousa SA,. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012; 133: 108-115.
13. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC,. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20.
14. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V,. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011; 13: 483-491.
15. Tan BX, Yao WX, Ge J, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011; 117: 5103-5111.
16. Garrett CR, Hassabo HM, Bhadkamkar NA, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer 2012; 106: 1374-1378.
17. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D,. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012; 18: 2905-2912.
18. Skinner HD, Crane CH, Garrett CR, et al. Metformin use and improved response to therapy in rectal cancer. Cancer Med 2013; 2: 99-107.
19. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res 2012; 18: 290-300.
20. Skinner HD, McCurdy MR, Echeverria AE, et al. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 2013; 52: 1002-1009.
21. Steinman MA, Lee SJ, John Boscardin W, et al. Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc 2012; 60: 1872-1880.
22. Sandulache VC, Kubik MW, Skinner HD, Malsky JA, Gelbard AH, Zevallos JP,. Impact of race/ethnicity on laryngeal cancer in patients treated at a Veterans Affairs Medical Center. Laryngoscope 2013. [Epub ahead of print]
23. Landis SH, El-Hariry IA, van Herk-Sukel MP, et al. Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck. Head Neck 2012; 34: 238-244.
24. Zafar SY, Abernethy AP, Abbott DH, et al. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer 2008; 8: 345.
25. Vitale-Cross L, Molinolo AA, Martin D, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev Res (Phila) 2012; 5: 562-573.